Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy
Antibodies · 07.05.2024 · 13 (2) · 39
DOI: 10.3390/antib13020039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibodies, online erschienen am 07.05.2024. Verfasst von Chuan Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA 15…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St. Baldrick's foundation, UPMC, St. Baldrick’s foundation, D-Feet Cancer Dalton Fox Foundation Grant.
Abstract (Originalsprache)
The anaplastic lymphoma kinase (ALK, CD247) is a potential target for antibody-based therapy. However, no antibody-based therapeutics targeting ALK have entered clinical trials, necessitating the development of novel antibodies with unique therapeutic merits. Single-domain antibodies (sdAb) bear therapeutic advantages compared to the full-length antibody including deeper tumor penetration, cost-effective production and fast washout from normal tissues. In this study, we identified a human immunoglobulin heavy chain variable domain (VH domain) (VH20) from an in-house phage library. VH20 exhibits good developability and high specificity with no off-target binding to ~6000 human membrane proteins. VH20 efficiently bound to the glycine-rich region of ALK with an EC50 of 0.4 nM and a KD of 6.54 nM. Both VH20-based bispecific T cell engager (TCE) and chimeric antigen receptor T cells (CAR Ts) exhibited potent cytolytic activity to ALK-expressing tumor cells in an ALK-dependent manner. VH20 CAR Ts specifically secreted proinflammatory cytokines including IL-2, TNFα and IFNγ after incubation with ALK-positive cells. To our knowledge, this is the first reported human single-domain antibody against ALK. Our in vitro characterization data indicate that VH20 could be a promising ALK-targeting sdAb with potential applications in ALK-expressing tumors, including neuroblastoma (NBL) and non-small cell lung cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA 15261, USA.
- Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
- Department of Biological Sciences, University of Pittsburgh Kenneth P. Dietrich School of Arts and Sciences, Pittsburgh, PA 15260, USA.
ORCID-Profile: Zening Wang
Förderung
- St. Baldrick's foundation
- UPMC, St. Baldrick’s foundation
- D-Feet Cancer Dalton Fox Foundation Grant
Zitieren
APA
Chen, C., Sun, Z., Wang, Z., Shin, S., Berrios, A., Mellors, J. W., Dimitrov, D. S., & Li, W. (2024). Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy. Antibodies, 13(2), 39. https://doi.org/10.3390/antib13020039
Vancouver
Chen C, Sun Z, Wang Z, Shin S, Berrios A, Mellors JW, et al. Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy. Antibodies. 2024;13(2):39. doi:10.3390/antib13020039
BibTeX
@article{Chen2024,
author = {Chen, Chuan and Sun, Zehua and Wang, Zening and Shin, Seungmin and Berrios, Abigail and Mellors, John W and Dimitrov, Dimiter S and Li, Wei},
title = {Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy},
journal = {Antibodies},
year = {2024},
volume = {13},
number = {2},
pages = {39},
doi = {10.3390/antib13020039}
}
EUVIMED